SCHEMBL936302

SCHEMBL936302

COc1c(B(O)O)cc(C(C)(C)C)cc1C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARG P13631 1/20 0.41
RXRA P19793 1/20 0.41
PPARG P37231 1/20 0.41
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
PTGS2 P35354 3/20 0.37
ALOX15 P16050 2/20 0.36
TP53 P04637 2/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
TNFRSF1A P19438 2/20 0.35
PTGS1 P23219 1/20 0.33
TUBB4A P04350 2/20 0.33
TUBB P07437 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947022 0.83 PTGS2 (0.47) RARGRXRAPPARGCA1CA2
SCHEMBL4855803 0.81 EGFR (0.34) RARGRXRAPPARGCA1CA2
SCHEMBL4863445 0.80 RXRA (0.44) RARGRXRAPPARGPTGS2CYP3A4
SCHEMBL31063374 0.79 GABRA1 (0.34) TP53GABRA1GABRB2TUBB4ATUBB
SCHEMBL4297642 0.78 ALOX15 (0.46) RARGRXRAPPARGCA1CA2
SCHEMBL14817161 0.78 RARG (0.40) RARGRXRAPPARGCA1CA2
SCHEMBL13688744 0.78 ALDH1A1 (0.42) RARGRXRAPPARGCA1CA2
SCHEMBL4852936 0.78 RXRA (0.46) RARGRXRAPPARGCYP3A4TSHR
SCHEMBL4856035 0.76 RXRA (0.47) RARGRXRAPPARGALOX15ALDH1A1
SCHEMBL4860379 0.76 RXRA (0.47) RARGRXRAPPARGLMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206766-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2025-06-26 US disclosed
CN-120157714-A Organic electroluminescent material and device 环球展览公司 2025-06-17 CN disclosed
EP-2456793-A1 CATALYSTS BASED ON 2-(2-ARYLOXY) QUINOLINE OR 2-(2-ARYLOXY) DIHYDROQUNIOLINE LIGANDS Equistar Chemicals, LP (US) 2012-05-30 EP disclosed
EP-2456795-A1 METHOD OF PREPARING NON-METALLOCENE CATALYSTS Equistar Chemicals, LP (US) 2012-05-30 EP disclosed
US-8158733-B2 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP (US) 2012-04-17 US disclosed
US-8158733-B2 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP (US) 2012-04-17 US disclosed
US-8158733-B2 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP (US) 2012-04-17 US disclosed
US-8153544-B2 Method for preparing non-metallocene catalysts EQUISTAR CHEMICALS, LP (US) 2012-04-10 US disclosed
US-8153544-B2 Method for preparing non-metallocene catalysts EQUISTAR CHEMICALS, LP (US) 2012-04-10 US disclosed
US-8153544-B2 Method for preparing non-metallocene catalysts EQUISTAR CHEMICALS, LP (US) 2012-04-10 US disclosed
WO-2011011039-A1 METHOD OF PREPARING NON-METALLOCENE CATALYSTS EQUISTAR CHEMICALS, LP (US) 2011-01-27 WO disclosed
WO-2011011039-A1 METHOD OF PREPARING NON-METALLOCENE CATALYSTS EQUISTAR CHEMICALS, LP (US) 2011-01-27 WO disclosed
US-20110021344-A1 Method for preparing non-metallocene ligands EQUISTAR CHEMICALS, LP 2011-01-27 US disclosed
US-20110021344-A1 Method for preparing non-metallocene ligands EQUISTAR CHEMICALS, LP 2011-01-27 US disclosed
US-20110021344-A1 Method for preparing non-metallocene ligands EQUISTAR CHEMICALS, LP 2011-01-27 US disclosed
US-20110021727-A1 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP 2011-01-27 US disclosed
US-20110021727-A1 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP 2011-01-27 US disclosed
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R RARG 302/4885RXRA 174/4885PPARG 61/4885
US-20250206766-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, L1CAM, OCIAD2 RARG 4033/4885RXRA 3764/4885PPARG 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.